During a presentation made in Linkoping, Sweden at the Sweden-Seattle
Diabetes Conference this past week-end, Professor Johnny Ludvigsson, the
Principal Investigator in Diamyd’s previously reported successful Phase II
study in type 1 diabetes, presented potentially scientifically
ground-breaking results from a recently completed analysis of the
immunological data from the same trial
Revolutionary Immunologic Data Explains Function Of Diamyd Diabetes Vaccine
– September 28, 2012Posted in: Zangani
